Experis Named Leader in Everest Group's 2025 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix Assessment

Lexaria Bioscience Corp. has completed the last patient last visit milestone in its Phase 1b GLP-1 study in Australia. The study aims to evaluate the safety and efficacy of DehydraTECH-processed GLP-1 analogs, with encouraging results from an interim analysis. The study's results are expected to be released by the end of 2025.

Kelowna, British Columbia – Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) has achieved a significant milestone in its Phase 1b glucagon-like peptide-1 (GLP-1) study in Australia. The company announced that the last patient last visit (LPLV) milestone has been reached, marking the completion of all patient dosing and clinical testing in the study, designated as GLP-1-H24-4. This milestone was achieved on schedule, with the study now entering the laboratory analysis phase [1].

The study, which aims to evaluate the safety and efficacy of DehydraTECH-processed GLP-1 analogs, has shown encouraging results in its interim analysis. The interim results indicated positive safety and tolerability data, with notable reductions in gastrointestinal adverse events compared to the Rybelsus® control arm [1]. The final results of the study are expected to be released by the end of 2025.

Lexaria's President and Chief Scientific Officer, John Docherty, expressed delight at the achievement of this milestone, stating, "We are delighted that this important milestone has been achieved on schedule, concluding all patient dosing and clinical testing in our Study. Study work continues with full sample and data analyses currently underway in order to reach our late 2025 final reporting objective" [1].

The study, conducted with 24-25 overweight, obese, pre- or type 2 diabetic patients in each of the five study arms (N=126), evaluated various DehydraTECH formulations, with one arm serving as the control using Rybelsus® tablets [1]. The study's primary objective is to determine if DehydraTECH-processed GLP-1 analogs are safe and effective over a 12-week duration, with secondary objectives including comparing the efficacy of DehydraTECH-processed GLP-1 analogs to Rybelsus® semaglutide and assessing the real-world outcomes of DehydraTECH processing [1].

Lexaria's DehydraTECH™ technology is a patented drug delivery platform that improves the way various drugs enter the bloodstream through oral delivery. The technology has demonstrated the ability to increase bio-absorption, reduce side-effects, and enhance drug delivery across the blood-brain barrier [2]. With a robust intellectual property portfolio and a licensed in-house research laboratory, Lexaria continues to push the boundaries of drug delivery and innovation.

References:
[1] https://www.thenewswire.com/press-releases/1BOxF09eP-lexaria-s-phase-1b-glp-1-study-achieves-important-last-patient-last-visit-milestone.html
[2] https://www.stocktitan.net/news/LEXX/lexaria-s-phase-1b-glp-1-study-achieves-important-last-patient-last-js6r5isl73b1.html